Adlai Nortye Group Ltd. entered into clinical trial collaboration and supply agreements with Eli Lilly and Company and Merck KGaA, Darmstadt, Germany to evaluate the combination of its investigational ADC AN4035 and cetuximab in an ongoing global Phase I trial for CEACAM5-enriched RAS-addicted solid tumors. Under the terms, Lilly will supply cetuximab at no cost for U.S. sites, while Merck KGaA will provide it for sites in Australia and China. The company operates as a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies.
